Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vitamin E in Hyperinsulinism/Hyperammonemia Syndrome
NCT04984798Phase 2Withdrawn
- Sponsor
- Children's Hospital of Philadelphia
- Start
- Nov 2022
- Primary completion
- Mar 2023
- Modality
- Orthosteric Ligands, Metabolically Activated Prodrugs
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of vitamin e in hyperinsulinism-hyperammonemia syndrome, sponsored by Children's Hospital of Philadelphia. Primary endpoint: protein-induced hyperinsulinemia. Planned start Nov 2022; status: withdrawn.
02
Drugs
vitamin e
03
Conditions
hyperinsulinism-hyperammonemia syndrome
Beyond the preview
Go deeper on NCT04984798.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04984798.